Leukemia - Table of Contents alert Volume 27 Issue 9

Advertisement BD FACSCanto™ is IVD cleared with 10-color capability.  Reliable performance, accuracy, and ease of use make the latest BD FACSCanto System a perfect 10 for today's busy clinical labs. Learn how you can achieve dependable outcomes while speeding workflow and reducing training requirements with clinical multi-color flow cytometry systems from BD Biosciences.  bdbiosciences.com/go/canto TABLE OF CONTENTS Volume 27, Issue 9 (September 2013) In this issue Spotlight Reviews Concise Review Original Articles Letters To The Editor Also new AOP Sign up for e-alerts Recommend to your library Web feed Follow on Twitter Subscribe Advertisement New Rising Impact Factor Leukemia celebrates a new Impact Factor of 10.164 and the journal is now ranked No. 2 in Hemtology and No. 8 in Oncology. Thank you for your support of the Leukemia. Read a free review: Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia *2012 Journal Citation Reports® (Thomson Reuters, 2013) Spotlight Reviews Top SPOTLIGHT ON EPIGENETICS IN HEMATOLOGIC MALIGNANCIES RUNX1 meets MLL: epigenetic regulation of hematopoiesis by two leukemia genes C P Koh, C Q Wang, C E L Ng, Y Ito, M Araki, V Tergaonkar, G Huang and M Osato Leukemia 2013 27: 1793-1802; advance online publication, July 2, 2013; 10.1038/leu.2013.200 Abstract | Full Text Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia E H Estey Leukemia 2013 27: 1803-1812; advance online publication, June 12, 2013; 10.1038/leu.2013.173 Abstract | Full Text Concise Review Top Combination of Azacitidine and Lenalidomide in Myelodysplastic Syndromes or acute Myeloid Leukemia—a wise Liaison? U Platzbecker and U Germing Leukemia 2013 27: 1813-1819; advance online publication, May 6, 2013; 10.1038/leu.2013.140 Abstract | Full Text Original Articles Top ACUTE LEUKEMIAS Detailed molecular characterisation of acute myeloid leukaemia with a normal karyotype using targeted DNA capture OPEN N Conte, I Varela, C Grove, N Manes, K Yusa, T Moreno, A Segonds-Pichon, A Bench, E Gudgin, B Herman, N Bolli, P Ellis, D Haddad, P Costeas, R Rad, M Scott, B Huntly, A Bradley and G S Vassiliou Leukemia 2013 27: 1820-1825; advance online publication, April 18, 2013; 10.1038/leu.2013.117 Abstract | Full Text MYELODYSPLASIAS Age, JAK2V617F and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis J Broséus, T Alpermann, M Wulfert, L Florensa Brichs, S Jeromin, E Lippert, M Rozman, F Lifermann, V Grossmann, T Haferlach, U Germing, E Luño, F Girodon and S Schnittger for the MPN and MPNr-EuroNet (COST Action BM0902) Leukemia 2013 27: 1826-1831; advance online publication, April 18, 2013; 10.1038/leu.2013.120 Abstract | Full Text Toll-like receptor alterations in myelodysplastic syndrome Y Wei, S Dimicoli, C Bueso-Ramos, R Chen, H Yang, D Neuberg, S Pierce, Y Jia, H Zheng, H Wang, X Wang, M Nguyen, S A Wang, B Ebert, R Bejar, R Levine, O Abdel-Wahab, M Kleppe, I Ganan-Gomez, H Kantarjian and G Garcia-Manero Leukemia 2013 27: 1832-1840; advance online publication, June 14, 2013; 10.1038/leu.2013.180 Abstract | Full Text Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells S Geyh, S Öz, R-P Cadeddu, J Fröbel, B Brückner, A Kündgen, R Fenk, I Bruns, C Zilkens, D Hermsen, N Gattermann, G Kobbe, U Germing, F Lyko, R Haas and T Schroeder Leukemia 2013 27: 1841-1851; advance online publication, March 29, 2013; 10.1038/leu.2013.193 Abstract | Full Text SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations M Meggendorfer, U Bacher, T Alpermann, C Haferlach, W Kern, C Gambacorti-Passerini, T Haferlach and S Schnittger Leukemia 2013 27: 1852-1860; advance online publication, April 30, 2013; 10.1038/leu.2013.133 Abstract | Full Text CHRONIC MYELOPROLIFERATIVE NEOPLASIAS Mutations and prognosis in primary myelofibrosis A M Vannucchi, T L Lasho, P Guglielmelli, F Biamonte, A Pardanani, A Pereira, C Finke, J Score, N Gangat, C Mannarelli, R P Ketterling, G Rotunno, R A Knudson, M C Susini, R R Laborde, A Spolverini, A Pancrazzi, L Pieri, R Manfredini, E Tagliafico, R Zini, A Jones, K Zoi, A Reiter, A Duncombe, D Pietra, E Rumi, F Cervantes, G Barosi, M Cazzola, N C P Cross and A Tefferi Leukemia 2013 27: 1861-1869; advance online publication, April 26, 2013; 10.1038/leu.2013.119 Abstract | Full Text CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia A Pardanani, T L Lasho, R R Laborde, M Elliott, C A Hanson, R A Knudson, R P Ketterling, J E Maxson, J W Tyner and A Tefferi Leukemia 2013 27: 1870-1873; advance online publication, April 22, 2013; 10.1038/leu.2013.122 Abstract | Full Text Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study OPEN A Tefferi, E Rumi, G Finazzi, H Gisslinger, A M Vannucchi, F Rodeghiero, M L Randi, R Vaidya, M Cazzola, A Rambaldi, B Gisslinger, L Pieri, M Ruggeri, I Bertozzi, N H Sulai, I Casetti, A Carobbio, G Jeryczynski, D R Larson, L Müllauer, A Pardanani, J Thiele, F Passamonti and T Barbui Leukemia 2013 27: 1874-1881; advance online publication, June 6, 2013; 10.1038/leu.2013.163 Abstract | Full Text AKT is a therapeutic target in myeloproliferative neoplasms I Khan, Z Huang, Q Wen, M J Stankiewicz, L Gilles, B Goldenson, R Schultz, L Diebold, S Gurbuxani, C M Finke, T L Lasho, P Koppikar, A Pardanani, B Stein, J K Altman, R L Levine, A Tefferi and J D Crispino Leukemia 2013 27: 1882-1890; advance online publication, June 10, 2013; 10.1038/leu.2013.167 Abstract | Full Text CYTOGENETICS AND MOLECULAR GENETICS The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia C Allen, R K Hills, K Lamb, C Evans, S Tinsley, R Sellar, M O'Brien, J L Yin, A K Burnett, D C Linch and R E Gale Leukemia 2013 27: 1891-1901; advance online publication, June 20, 2013; 10.1038/leu.2013.186 Abstract | Full Text LYMPHOMA Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial M Wang, N Fowler, N Wagner-Bartak, L Feng, J Romaguera, S S Neelapu, F Hagemeister, M Fanale, Y Oki, B Pro, J Shah, S Thomas, A Younes, C Hosing, L Zhang, K J Newberry, M Desai, N Cheng, M Badillo, M Bejarano, Y Chen, K H Young, R Champlin, L Kwak and L Fayad Leukemia 2013 27: 1902-1909; advance online publication, April 2, 2013; 10.1038/leu.2013.95 Abstract | Full Text Letters To The Editor Top Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation T Schroeder, J Fröbel, R-P Cadeddu, A Czibere, A Dienst, U Platzbecker, G Bug, L Uharek, R Fenk, U Germing, N Kröger, R Haas and G Kobbe Leukemia 2013 27: 1910-1913; advance online publication, March 1, 2013; 10.1038/leu.2013.64 Full Text Suppression of Pu.1 function results in expanded myelopoiesis in zebrafish J Sun, W Liu, L Li, J Chen, M Wu, Y Zhang, A Y H Leung, W Zhang, Z Wen and W Liao Leukemia 2013 27: 1913-1917; advance online publication, March 4, 2013; 10.1038/leu.2013.67 Full Text A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice OPEN A Mupo, L Celani, O Dovey, J L Cooper, C Grove, R Rad, P Sportoletti, B Falini, A Bradley and G S Vassiliou Leukemia 2013 27: 1917-1920; advance online publication, March 12, 2013; 10.1038/leu.2013.77 Full Text Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies M Roschewski, M Farooqui, G Aue, F Wilhelm and A Wiestner Leukemia 2013 27: 1920-1923; advance online publication, March 14, 2013; 10.1038/leu.2013.79 Full Text Applicability of a reproducible flow cytometry scoring system in the diagnosis of refractory cytopenia of childhood A M Aalbers, M M van den Heuvel-Eibrink, V de Haas, J G te Marvelde, A X de Jong, M van der Burg, M Dworzak, H Hasle, F Locatelli, B De Moerloose, M Schmugge, J Stary, M Zecca, C M Zwaan, A A van de Loosdrecht, J J M van Dongen, C M Niemeyer and V H J van der Velden Leukemia 2013 27: 1923-1925; advance online publication, March 15, 2013; 10.1038/leu.2013.81 Full Text Autoimmunity and persistent RAS-mutated clones long after the spontaneous regression of JMML M Takagi, J Piao, L Lin, H Kawaguchi, C Imai, A Ogawa, A Watanabe, K Akiyama, C Kobayashi, M Mori, K Ko, M Sugimoto and S Mizutani Leukemia 2013 27: 1926-1928; advance online publication, March 18, 2013; 10.1038/leu.2013.82 Full Text Mobilization studies in C3-deficient mice unravel the involvement of a novel crosstalk between the coagulation and complement cascades in mobilization of hematopoietic stem/progenitor cells S Borkowska, M Suszynska, M Wysoczynski and M Z Ratajczak Leukemia 2013 27: 1928-1930; advance online publication, March 20, 2013; 10.1038/leu.2013.84 Full Text Why do we see JAK2 exon 12 mutations in myeloproliferative neoplasms? I Vorechovsky, A V Jones and N C P Cross Leukemia 2013 27: 1930-1932; advance online publication, March 20, 2013; 10.1038/leu.2013.85 Full Text High incidence of RAS signalling pathway mutations in MLL-rearranged acute myeloid leukemia V Grossmann, S Schnittger, F Poetzinger, A Kohlmann, A Stiel, C Eder, A Fasan, W Kern, T Haferlach and C Haferlach Leukemia 2013 27: 1933-1936; advance online publication, March 28, 2013; 10.1038/leu.2013.90 Full Text Impact of IKZF1 deletions and PAX5 amplifications in pediatric B-cell precursor ALL treated according to NOPHO protocols I Öfverholm, A N Tran, M Heyman, V Zachariadis, M Nordenskjöld, A Nordgren and G Barbany Leukemia 2013 27: 1936-1939; advance online publication, March 29, 2013; 10.1038/leu.2013.92 Full Text Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified? OPEN A Tefferi Leukemia 2013 27: 1939-1940; advance online publication, April 22, 2013; 10.1038/leu.2013.112 Full Text Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics V Grossmann, U Bacher, C Haferlach, S Schnittger, F Pötzinger, S Weissmann, A Roller, C Eder, A Fasan, M Zenger, M Staller, W Kern, A Kohlmann and T Haferlach Leukemia 2013 27: 1940-1943; advance online publication, May 7, 2013; 10.1038/leu.2013.144 Full Text Novel recurrent mutations in the RAS-like GTP-binding gene RIT1 in myeloid malignancies I Gómez-Seguí, H Makishima, A Jerez, K Yoshida, B Przychodzen, S Miyano, Y Shiraishi, H D Husseinzadeh, K Guinta, M Clemente, N Hosono, M A McDevitt, A R Moliterno, M A Sekeres, S Ogawa and J P Maciejewski Leukemia 2013 27: 1943-1946; advance online publication, June 14, 2013; 10.1038/leu.2013.179 Full Text Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia O Kosmider, R Itzykson, V Chesnais, T Lasho, R Laborde, R Knudson, A Gauthier, J Merlevede, L Ades, M Morabito, M Fontenay, A Tefferi, N Droin and E Solary Leukemia 2013 27: 1946-1949; advance online publication, June 18, 2013; 10.1038/leu.2013.182 Full Text Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab OPEN A M Fink, S Böttcher, M Ritgen, K Fischer, N Pflug, B Eichhorst, C-M Wendtner, D Winkler, A Bühler, T Zenz, P Staib, J Mayer, M Hensel, G Hopfinger, M Wenger, G Fingerle-Rowson, H Döhner, M Kneba, S Stilgenbauer, R Busch and M Hallek Leukemia 2013 27: 1949-1952; advance online publication, June 21, 2013; 10.1038/leu.2013.190 Full Text Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.